Innovation, Entrepreneurship & Networks
summary
A biotech entrepreneur who founded a company in 2004 that later reached about €8 billion valuation describes moving from running firms to investing. The talk advocates two research priorities—extending human lifespan toward 150–200 years and enhancing human performance—cites modafinil as improving exam recall by about 10–15% while impairing initial learning, and suggests daily alkalizing (e.g., a lemon in water) can reduce immune-protein clumping and make immune age 10–20 years younger. It also predicts rapid change from biotechnology combined with machines and resulting major societal divisions.
AI-written summary · about
chapters (13)
- 0:00Innovation & entrepreneurship intro
- 1:08Biotech startup in 4 weeks
- 2:13Study vs entrepreneurial passion
- 3:38Passion and aptitude
- 4:42From entrepreneur to investor
- 5:50Longevity and performance
- 8:48Longevity research
- 10:59Life extension to 150+
- 12:26Society after extreme longevity
- 13:14Exponential tech & biotech growth
- 14:26Humans merging with machines
- 15:17Tech progress and society
- 16:40Future: human split
related talks
16mHow Biology Benefits from Technological Discoveries
20mHow not to die
39mThe Next Frontier of Longevity: Harnessing science & technology for health & wellness
09mHealthy Longevity – the Next Big Thing: For Business, Society, Health Systems… and Everybody
21mYounger Tomorrow! The Age of Longevity
25mBiology's ChatGPT Moment
34mThe True Revolution Lies Ahead of Us
21mIdeas that Matter